List view / Grid view

Functional Genomics Centre (FGC)



On the CRISPR horizon: democratising access to genome-editing technologies

16 December 2022 | By ,

Dr Douglas Ross-Thriepland and Dr David Walter, from the Functional Genomics Centre (FGC) – a joint venture between Cancer Research UK’s (CRUK) drug discovery engine, Cancer Research Horizons, and AstraZeneca – speak to Drug Target Review about their work. The centre’s focus is on genetic screening; cancer models; CRISPR reagent…